Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab

Inclusion Criteria:

* Age 18 years or older.
* Patient scheduled to start an epidermal growth factor receptor inhibitor (must be one of these three: panitumumab, erlotinib, cetuximab) within the next 3 days or patient has already started the epidermal growth factor receptor inhibitor but has not been on it for longer than 3 days and has no signs or symptoms potentially suggestive of EGFR inhibitor toxicity.
* Ability to reliably apply Menadione Topical Lotion / placebo twice a day to the face.
* Ability to complete questionnaire(s) by themselves or with assistance.
* Negative pregnancy test (serum or urine) done ≤ 7 days prior to registration, for women of childbearing potential only.
* Willing to have photographs taken to assess rash.

Exclusion Criteria:

* Any active facial and/or chest rash, including adult acne, at the time of randomization.
* Cutaneous metastases, skin cancer, or a history of precancerous skin lesions involving the face and/or chest.
* Use of topical corticosteroids on the face and/or chest at the time of study entry or their anticipated use in the next 8 weeks.
* Any type of ongoing therapy for rash.
* Any of the following:

  * Pregnant women
  * Nursing women
  * Men or women of childbearing potential who are unwilling to employ adequate contraception since this study involves agents that have known genotoxic, mutagenic and teratogenic effects
* Use of any antibiotic at the time of study or their anticipated use in the 8 weeks immediately following study enrollment.